Ocugen Revenue and Competitors
Estimated Revenue & Valuation
- Ocugen's estimated annual revenue is currently $22.6M per year.
- Ocugen's estimated revenue per employee is $155,000
Employee Data
- Ocugen has 146 Employees.
- Ocugen grew their employee count by 1% last year.
Ocugen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman the Board, CEO and Co-founder | Reveal Email/Phone |
2 | VP, Head Program Management & Chief Staff | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Accounting Officer | Reveal Email/Phone |
5 | VP, CMC and Technical Operations | Reveal Email/Phone |
6 | Head Quality Assurance (GMP and GCP, Senior Director) | Reveal Email/Phone |
7 | VP, Manufacturing and Supply | Reveal Email/Phone |
8 | AVP, IT & Facilities | Reveal Email/Phone |
9 | VP Quality Assurance & Regulatory Affairs | Reveal Email/Phone |
10 | Head People and Culture | Reveal Email/Phone |
Ocugen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1200M | 1397 | -6% | $2.4B | $8.4B |
#2 | $11830M | 9797 | 26% | $2.7B | $83B |
#3 | $69340M | 112676 | 4% | N/A | $308.4B |
#4 | $4.2M | 149 | -22% | $52.7M | N/A |
What Is Ocugen?
Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many†and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
keywords:N/A
N/A
Total Funding
146
Number of Employees
$22.6M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ocugen News
Ocugen announced that it had secured the rights to commercialize Covaxin, a coronavirus vaccine developed by its India-based partner Bharat...
NEW DELHI : Ocugen, a biotechnology company and Hyderabad based Bharat Biotech on Monday announced to have entered into an agreement that...
Ocugen has added the rights for Covaxin in Mexico to its co-development deal for the Covid-19 vaccine with Bharat Biotech of India.
Other Companies in Malvern
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $31.3M | 146 | 5% | N/A |
#2 | $43.4M | 146 | -4% | N/A |
#3 | $49.4M | 155 | 17% | N/A |
#4 | $38.2M | 158 | -1% | N/A |
#5 | $50.4M | 158 | 5% | N/A |